These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 36495086

  • 1. Dopamine partial agonists: a discrete class of antipsychotics.
    Taylor D, Chithiramohan R, Grewal J, Gupta A, Hansen L, Reynolds GP, Pappa S.
    Int J Psychiatry Clin Pract; 2023 Sep; 27(3):272-284. PubMed ID: 36495086
    [Abstract] [Full Text] [Related]

  • 2. Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia.
    Keks N, Hope J, Schwartz D, McLennan H, Copolov D, Meadows G.
    CNS Drugs; 2020 May; 34(5):473-507. PubMed ID: 32246399
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and tolerability of brexpiprazole - a new antipsychotic drug from the group of dopamine D2 receptor partial agonists.
    Bieńkowski P, Wichniak A.
    Psychiatr Pol; 2024 Apr 30; 58(2):237-248. PubMed ID: 39003508
    [Abstract] [Full Text] [Related]

  • 4. The position statement of the Working Group of the Polish Psychiatric Association on the use of D2/D3 dopamine receptor partial agonists in special populations.
    Wichniak A, Siwek M, Rymaszewska J, Janas-Kozik M, Wolańczyk T, Bieńkowski P, Dudek D, Heitzman J, Szulc A, Samochowiec J.
    Psychiatr Pol; 2021 Oct 31; 55(5):967-987. PubMed ID: 34997737
    [Abstract] [Full Text] [Related]

  • 5. Brexpiprazole: a new leaf on the partial dopamine agonist branch.
    Hope J, Castle D, Keks NA.
    Australas Psychiatry; 2018 Feb 31; 26(1):92-94. PubMed ID: 29017334
    [Abstract] [Full Text] [Related]

  • 6. The position statement of the Working Group of the Polish Psychiatric Association on the use of D2/D3 dopamine receptor partial agonists in the treatment of mental disorders.
    Wichniak A, Samochowiec J, Szulc A, Dudek D, Heitzman J, Janas-Kozik M, Wolańczyk T, Rymaszewska J, Siwek M, Bieńkowski P.
    Psychiatr Pol; 2021 Oct 31; 55(5):941-966. PubMed ID: 34997736
    [Abstract] [Full Text] [Related]

  • 7. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
    Cosi C, Carilla-Durand E, Assié MB, Ormiere AM, Maraval M, Leduc N, Newman-Tancredi A.
    Eur J Pharmacol; 2006 Mar 27; 535(1-3):135-44. PubMed ID: 16554049
    [Abstract] [Full Text] [Related]

  • 8. Cariprazine: A new partial dopamine agonist with a familiar profile.
    Hope J, Keks NA.
    Australas Psychiatry; 2022 Jun 27; 30(3):382-385. PubMed ID: 35156402
    [Abstract] [Full Text] [Related]

  • 9. [A new approach to antischizophrenic therapeutics: D2 dopamine receptor partial agonists].
    Costentin J.
    Ann Pharm Fr; 2009 Sep 27; 67(5):310-9. PubMed ID: 19695367
    [Abstract] [Full Text] [Related]

  • 10. Receptor density influences the recruitment bias of aripiprazole and brexpiprazole at the dopamine D2L receptor.
    Ferraiolo M, Ponthot R, Atik H, Koener B, Hanson J, Hermans E.
    Fundam Clin Pharmacol; 2022 Dec 27; 36(6):976-984. PubMed ID: 35767599
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?
    Mohr P, Masopust J, Kopeček M.
    Front Psychiatry; 2021 Dec 27; 12():781946. PubMed ID: 35145438
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Do dopamine partial agonists have partial efficacy as antipsychotics?
    Stahl SM.
    CNS Spectr; 2008 Apr 27; 13(4):279-82. PubMed ID: 18408646
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Transformation of a Dopamine D2 Receptor Agonist to Partial Agonists as Novel Antipsychotic Agents.
    Liu R, Qi J, Wang H, Fan L, Zhang P, Yu J, Tan L, Wang S, Cheng J.
    J Med Chem; 2023 May 11; 66(9):6274-6287. PubMed ID: 37130037
    [Abstract] [Full Text] [Related]

  • 19. Dopamine agonists and antipsychotics.
    Molitch ME.
    Eur J Endocrinol; 2020 Sep 11; 183(3):C11-C13. PubMed ID: 32508315
    [Abstract] [Full Text] [Related]

  • 20. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic.
    Keck PE, McElroy SL.
    Expert Opin Investig Drugs; 2003 Apr 11; 12(4):655-62. PubMed ID: 12665420
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.